CCL19抗体;CCL19 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P13197(CCL19 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

CCL19. a member of the CC chemokine family, plays a critical role in immune cell trafficking and lymphoid tissue organization by binding to its receptor CCR7. It is primarily produced by stromal cells in secondary lymphoid organs and facilitates the migration of dendritic cells, T cells, and B cells, enabling adaptive immune responses. Dysregulation of CCL19 is implicated in autoimmune diseases, chronic inflammation, and cancer metastasis, particularly in lymph node involvement.

CCL19 antibodies are valuable tools for studying its biological functions and therapeutic potential. Monoclonal antibodies targeting CCL19 can block its interaction with CCR7. modulating immune cell recruitment and inflammatory processes. In research, these antibodies are used in ELISA, flow cytometry, and immunohistochemistry to quantify CCL19 levels or map its expression in tissues. Therapeutically, they are explored for conditions like rheumatoid arthritis, inflammatory bowel disease, and cancers where CCR7-CCL19 signaling promotes tumor dissemination.

Recent studies also highlight CCL19's role in tertiary lymphoid structure formation, linking it to immunotherapy responses. However, challenges remain in balancing efficacy with potential off-target effects. Overall, CCL19 antibodies offer dual utility as investigative reagents and promising candidates for immune-targeted therapies.